Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Featured News Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsAuthored by Nathan Reiff. Publication Date: 3/12/2026. 
Quick Look - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to reach $366 billion within eight years. Companies often take a niche approach, developing medicines aimed at specific cancer types with dedicated mechanisms of action. Fortunately, several promising treatments have shown impressive potential—and with that comes the possibility of significant sales. Two small biotech companies have seen substantial share-price momentum thanks to their leading oncology medicines. Besides offering potent treatment potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. In both cases, however, notable challenges remain, making these typical biotech investments high-risk ventures that also carry the potential for outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Why This "Magical" Element is the Most Important in America
It's critical for jet engines, steel, electric batteries, and AI chips.
Yet Russia, China, and Indonesia control 80% of its production.
Only ONE company in America can change that.
Here's why an ex-CIA economist believes the White House will invest in it in the days ahead... sending shares soaring. Discover the whole story here. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 dipped about 1%. That rally added to IOVA's year-to-date (YTD) performance, during which the shares have more than doubled. Still, with a consensus price target of $8.88, Wall Street expects more—the target implies roughly 71% upside from current levels. The primary catalyst for Iovance's price movement is Amtagvi, a T‑cell immunotherapy for certain melanomas. Amtagvi has been approved in the U.S. since 2024 and is gaining traction in sales, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL‑2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Its broader potential may lie beyond melanoma: Amtagvi received FDA Fast Track Designation for non‑small cell lung cancer and could be effective against several other tumor types. Some of Iovance's outperformance this year followed its Q4 2025 earnings report, issued in late February, in which the company posted smaller-than-expected losses per share and reported $5 million in revenue. For the full year, revenue rose roughly 30% year over year (YOY). Iovance is a relatively small (~$2 billion) biotech and remains categorized as a penny stock. Despite the rally, analysts are still cautious: about half of its roughly dozen analyst ratings are Hold or Sell. Risks are significant—not only the usual uncertainties surrounding smaller biotechs but also manufacturing hurdles. Amtagvi is a personalized, costly, and complex therapy to produce, and these constraints could limit Iovance's ability to generate profit even as demand increases. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) slipped about 20% in March, but its YTD performance dwarfs Iovance: IBRX shares are up nearly 300% in 2026 so far. Analysts' price target of $13.60 implies roughly 70% upside from the stock's current level even after the recent run. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the E.U. regulator granted conditional marketing authorization, the latest in a series of approvals worldwide. Anktiva is fueling the firm's revenue: it generated $113 million in sales last year, about a 700% YOY increase. Like Amtagvi, Anktiva may have potential in additional cancer indications, and ImmunityBio is actively exploring alternative designations. Despite the strong gains over recent quarters, IBRX remains speculative and risky. The company reported a full-year net loss of $351 million for 2025 as R&D expenses continue to rise. Wall Street analysts are nonetheless more bullish here than on Iovance—six of seven covering analysts rate the shares a Buy or equivalent.
| 
